Challenges of Coverage Policy Development for Next-Generation Tumor Sequencing Panels: Experts and Payers Weigh In
- 3 March 2015
- journal article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 13 (3), 311-318
- https://doi.org/10.6004/jnccn.2015.0043
Abstract
Background: Next-generation tumor sequencing (NGTS) panels, which include multiple established and novel targets across cancers, are emerging in oncology practice, but lack formal positive coverage by US payers. Lack of coverage may impact access and adoption. This study identified challenges of NGTS coverage by private payers. Methods: We conducted semi-structured interviews with 14 NGTS experts on potential NGTS benefits, and with 10 major payers, representing more than 125,000,000 enrollees, on NGTS coverage considerations. We used the framework approach of qualitative research for study design and thematic analyses and simple frequencies to further describe findings. Results: All interviewed payers see potential NGTS benefits, but all noted challenges to formal coverage: 80% state that inherent features of NGTS do not fit the medical necessity definition required for coverage, 70% view NGTS as a bundle of targets versus comprehensive tumor characterization and may evaluate each target individually, and 70% express skepticism regarding new evidence methods proposed for NGTS. Fifty percent of payers expressed sufficient concerns about NGTS adoption and implementation that will preclude their ability to issue positive coverage policies. Conclusions: Payers perceive that NGTS holds significant promise but, in its current form, poses disruptive challenges to coverage policy frameworks. Proactive multidisciplinary efforts to define the direction for NGTS development, evidence generation, and incorporation into coverage policy are necessary to realize its promise and provide patient access. This study contributes to current literature, as possibly the first study to directly interview US payers on NGTS coverage and reimbursement.Keywords
This publication has 47 references indexed in Scilit:
- HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?International Journal of Technology Assessment in Health Care, 2014
- Integrating genomics into clinical oncology: Ethical and social challenges from proponents of personalized medicineUrologic Oncology, 2014
- Precision Medicine for Cancer Patients: Lessons Learned and the Path ForwardJNCI Journal of the National Cancer Institute, 2013
- New Approaches to Molecular DiagnosisJAMA, 2013
- The arrival of genomic medicine to the clinic is only the beginning of the journeyGenetics in Medicine, 2013
- Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future TherapiesJournal of Clinical Oncology, 2013
- Life Technologies promises $1,000 genomeNature Biotechnology, 2012
- NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in OncologyJournal of the National Comprehensive Cancer Network, 2011
- Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion OncogeneJAMA, 2011
- Capacity building for assessing new technologies: approaches to examining personalized medicine in practicePersonalized Medicine, 2010